Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06781983 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Innate Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 7
- Study locations
NCT06781983: Recruiting Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Innate Pharma.
NCT06781983 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Innate Pharma. The registered enrollment target is 145 participants, below the 229-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (37% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06781983, a Phase 1 study of Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Innate Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Primary Outcome
To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs.
Conditions Studied
Interventions
- DRUG IPH4502
Study Locations (7)
Other
- Centre Léon Bérard - Lyon
- Gustave Roussy Cancer Institute - Villejuif
Massachusetts
- Massachusetts General Hospital - Boston - Boston
New Jersey
- John Theurer Cancer Center - Hackensack
New York
- Mount Sinai Tisch Cancer Center - New York
Texas
- NEXT Oncology - Dallas - Dallas
Virginia
- NEXT Oncology - Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2029-04 |
| Phase | Phase 1 |
What NCT06781983 shows while recruiting
NCT06781983 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 229-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IPH4502 is the first listed.
NCT06781983 lists 7 locations in 6 states (Other, Massachusetts, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06781983 about?
NCT06781983 is a clinical study titled "Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors". This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
What is the current status of trial NCT06781983?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2025-01-24. Estimated completion is 2029-04.
What conditions does trial NCT06781983 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06781983?
The interventions under investigation include: IPH4502 (DRUG).
Who is sponsoring clinical trial NCT06781983?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06781983 being conducted?
This trial has 7 study locations across Massachusetts, New Jersey, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06781983's enrollment target sits among peer trials
145 12th of 19 higher than 7 of 19 other Advanced or Metastatic Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced or Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RECRUITING · Phase 1
-
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI